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S. Luja´n,1* E. Puras,1 L. Lo´pez-Besco´s,2 J.C. Belincho´n,3 M. Gutie´rrez1
and C. Guijarro3Departments of 1Vascular Surgery, 2Cardiology, and 3Internal medicine, Fundacio´n Hospital Alcorco´n,
C/Budapest s/n, 28922 Alcorco´n, Madrid, SpainObjectives. To determine clinical parameters that could predict occult vascular lesions (OVL) in patients with symptomatic
atherosclerosis.
Patients and methods. Prospective evaluation of 269 consecutive patients with symptomatic atherosclerosis (cerebral
32%, peripheral vascular 15%, and coronary 53%): complete laboratory, ultrasound exams (carotids, aorta, heart), ankle-
brachial index. OVL were defined as: abdominal aortic aneurysm, carotid artery stenosis O50%, or left ventricular
segmental contraction abnormalities when affecting a different vascular bed from the symptomatic. Clinical predictors of
OVL were evaluated by logistic regression analysis.
Results. OVL were found in 35 patients (13%): 12 abdominal aortic aneurysms, 21 carotid artery stenosis and 15
segmental left ventricular contraction abnormalities. OVL were associated with peripheral vascular disease (intermittent
claudication or reduced ankle-brachial index), cigarette smoking, increased pulse pressure, microalbuminuria and
hyperhomocysteinemia. By multivariate analysis, intermittent claudication (odds ratio 5.8; 95% CI 2.6–12.8) and
microalbuminuria (OR 4.2; 95% CI 1.7–10.5) were strong independent predictors of OVL. Similar results were obtained
when peripheral vascular disease was defined as reduced ankle-brachial index (OR 5.3; 95% CI 2.4–11.7).
Conclusions. Clinical and subclinical peripheral vascular disease, as well as microalbuminuria are strong independent
predictors of OVL in atherosclerotic patients. A screening study of OVL may be warranted in these patients.Keywords: Occult vascular lesions; Atherosclerosis; Microalbuminuria; Intermittent claudication; Ankle-brachial index.Introduction
Although atherosclerosis is a systemic disease, a
thorough assessment of all vascular beds is not
generally performed beyond the symptomatic terri-
tory. Patients with symptomatic atherosclerosis are
more likely to have significant vascular lesions in
clinically silent territories than the general population,
given the systemic nature of the disease.1 However, it
is unclear whether an exhaustive evaluation of
clinically silent territories would translate into a
meaningful clinical benefit. In the search for such
occult vascular lesions, four important issues must be
considered: cost, invasiveness, and accuracy of the
screening test; prevalence of the disease; efficacy of
interventions to treat the disease; cost of interven-
tions.2 In this regard the screening of carotid arterying author. Dr Salvador Luja´n, MD, Department of
gery, Fundacio´n Hospital Alcorco´n, C/Budapest s/n,
o´n, Madrid, Spain.
: slujanhuertas@fhalcorcon.es
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with lower limb arterial occlusive disease has been
demonstrated to be cost-effective.3,4 Surprisingly, few
studies have addressed a thorough evaluation of all
vascular beds beyond the symptomatic territory.
In this study, we performed a non-invasive evalu-
ation of all vascular beds in patients with symptomatic
atherosclerosis of any territory in order to determine
clinical predictors of important vascular lesions
(carotid artery stenosis, abdominal aortic aneurysm,
cardiac segmental contractility abnormalities) in
asymptomatic territories.Patients and Methods
The clinical setting for this study was a University
Hospital responsible for the medical care of a 250,000
population community. The inclusion criteria were
symptomatic atherosclerosis of any territory; coronary
(myocardial infarction or unstable angina), cerebralEur J Vasc Endovasc Surg 30, 57–62 (2005)
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ischemic attack) or peripheral vascular (claudication
grade IIB) attended between July 2000 and June 2002.
Exclusion criteria were age O70 years, serum creati-
nine O3 mg/dl or substitutive renal treatment, life
expectancy less than 3 years, inability to understand
protocol-derived instructions, rejection of informed
consent. All patients were evaluated by the same
physician 1 month after the atherothrombotic ischemic
event (index event) under a protocol that included:
informed consent, detailed medical history of personal
and family risk factors, anthropometrics (weight,
height, body-mass index, waist circumference), blood
pressure determinations (average of two ‘casual’
measurements in the outpatients clinic; pulse pressure
was defined as the difference between systolic and
diastolic blood pressure), echocardiogram (Hewlett
Packard Sonos 5500), carotid duplex scan (ATL 3500),
sonographic measurement of abdominal aortic diam-
eter, ankle-brachial index, fasting laboratory determi-
nations (fractionated cholesterol, triglycerides, Apo B,
Apo A1, Lp(a), creatinine, glucose, glycated hemo-
globin, high-sensitivity C-reactive protein, homocys-
t(e)in and microalbuminuria (albumin/creatinine
ratio). Important vascular lesions were defined as the
presence of internal carotid stenosisO50% (Washing-
ton University criteria),5 abdominal aortic aneurysm
(O3 cm diameter), left ventricular segmental contrac-
tion abnormalities. These vascular lesions were con-
sidered as ‘occult’ (OVL) when they were not clinically
suspected and were present in a different vascular
territory from the one that qualified for the inclusion in
the study. Besides its prognostic importance, the
presence of subclinical peripheral vascular disease
was not included as OVL since, it did not imply
significant changes in the therapeutic or follow-up
attitude.Statistical analysis
Data were maintained in a computerized database,
and were analyzed with SPSS statistical software
(SPSS for Windows 11.5). Statistical comparisons
were performed with the two-tailed Student’s t test
for comparison of continuous variables, and either chi2
or the Fisher’s exact test for comparison of discrete
variables. Continuous variables with non-normal
distribution were logarithmically transformed for the
comparisons and are reported as median (interquartile
range). Variables associated (p!0.1) with the presence
of OVL were entered into a multivariate forward
stepwise logistic regression model. p!0.05 was con-
sidered statistically significant.Eur J Vasc Endovasc Surg Vol 30, July 2005Results
Among 521 potential candidates evaluated, 421 met
the inclusion criteria. Hereafter, all data will be
referred to the 269 patients (64%) who consented to
participate in the study. The index atherothrombotic
event was coronary in 52% (30% unstable angina, 22%
myocardial infarction), cerebrovascular in 32% (11%
transient ischemic attack, 7% lacunar infarct, 14% non-
lacunar non-cardioembolic stroke), and lower
ischemic arterial disease (grade IIb) in 15%. Mean
age was 60G8 years, 80% of the patients were male,
77% were or had been smokers, 76% had hypercho-
lesterolemia, 63% hypertension, 29% diabetes mellitus
and 20% a family history of coronary disease.
In the non-invasive study, 12 patients had an
abdominal aortic aneurysm, 21 patients had a greater
than 50% internal carotid artery stenosis (16 stenosis
O50%, four stenosis O80%, one asymptomatic
internal carotid artery occlusion), and 15 patients
had segmental contractility abnormalities. 35 patients
(13%) had one or more OVL in different territories
from the one that qualified them for inclusion in the
study. The prevalence of OVL were greater in patients
included for lower limb arterial ischemic disease (22%)
than those included for coronary artery disease (15%)
or cerebrovascular disease (6%; pZ0.027) (Fig. 1).
The relationships between data from the past
medical history and the presence of OVL are shown
in Table 1. Patients with a personal history of
intermittent claudication were significantly more
likely to have OVL (63 vs. 21%, p!0.001). In addition,
cigarette smoking (andmarginally cumulative years of
tobacco use) was also associated with the presence of
OVL. Other risk factors were equally distributed
among patients with and without OVL.
The relationship between OVL and other clinical
and laboratory variables is shown in Table 2. Of note,
lipid values were similar for both groups. In contrast,
patients with OVL had increased pulse pressure (pZ
0.005), marginally higher systolic blood pressure (pZ
0.059) but similar diastolic blood pressure. Microalbu-
minuria was significantly more frequent among
patients with OVL (p!0.001). However, glucose or
glycated hemoglobin did not differ between both
groups. Interestingly, OVL was also associated with
increased homocysteine (pZ0.005) and high C-reac-
tive protein (pZ0.09), although the latter did not reach
statistical significance.
When all variables associated (p!0.1) with OVL
were evaluated in a logistic regression model, the
presence of peripheral vascular disease and micro-
albuminuria were the only independent predictors of
OVL (Table 3). The model was essentially identical
Fig. 1. Patients with occult vascular lesions according to the
index territory.
Occult Vascular Lesions 59whether peripheral vascular disease was defined
clinically (intermittent claudication) or by a reduced
ankle-brachial index. The predictive power of both
microalbuminuria and peripheral vascular disease
remained virtually unchanged after adjusting for age
and gender.Discussion
Although atherosclerosis is a systemic disease, it is
unclear to what extent a thorough evaluation of silent
clinical territories should be performed. Patients with
symptomatic atherosclerosis of one territory are likely
to have some degree of ‘subclinical disease’ in
asymptomatic territories. Therefore, the main reason
for the study of silent vascular beds should be directed
to the detection of potentially dangerous lesions and
the eventual prevention of clinically severe events. For
this purpose we have defined occult vascular lesions
in a restrictive manner: (1) corresponding to unsus-
pected lesions in clinically silent territories, and (2)
severe enough to deserve a specific treatment or at
least specific follow-up. Most patients (87%) in our
series did not fulfill these strict criteria, furtherTable 1. Relationship between past medical history and occult vascu
Medical history data Occult vascu
No
n 234
Age (years) 59.5G8.4
Male sex 184 (79%)
Family history of early cardiovascular disease 49 (21%)
Personal history of stroke 24 (10%)
Coronary artery disease 51 (22%)
Intermittent claudication 48 (21%)
Atrial fibrillation 13 (6%)
Cigarette smoking 102 (44%)
Cumulative cigarette exposure (years) 27G19
Hypertension 143 (61%)
Dyslipemia 178 (76%)
Diabetes mellitus 69 (30%)
X syndrome 91 (39%)
Data are expressed as meanGSD or number of cases (percentage). NSsuggesting the need of concentrating the efforts on
patients of the highest risk. In our series, we have
included consecutive patients with clinical athero-
sclerosis of any territory, providing a representative
sample of the full spectrum of atherosclerosis. A
remarkable finding in our study is the different
prevalence of OVL depending on the initial sympto-
matic territory. In this regard, the prevalence of OVL
was particularly high in patients with lower limb
ischemic disease. We have found a prevalence of 22%
of OVL in patients with lower limb ischemic disease.
Wolf et al.4 identified abdominal aortic aneurysms in
15% a population of 531 male smokers older than 65
years with lower limb ischemic disease. Other studies
have reported that 15–25% of patients with lower limb
ischemic disease have significant carotid artery steno-
sis.3,6 Recent data from the SMARTstudy show similar
results to ours: the presence of peripheral vascular
disease is associated with OVL like carotid stenosis or
abdominal aortic aneurysms.7 Although studies differ
in the lesions included in the screening protocol, it is
clear that patients with lower limb ischemia have a
considerably higher rate of occult vascular lesions.
These findings are of particular interest considering
the recent results of the asymptomatic carotid surgery
trial showing that immediate carotid endarterectomy
halved the net 5-year stroke risk from 12 to 6% in
patients with an asymptomatic 70% or greater carotid
artery stenosis.8
Not surprisingly, cigarette smoking was associated
with OVL. The fact that tobacco use was not selected in
the final logistic regression model should not under-
mine the hazards of smoking. It is likely that the risk
conferred by tobacco use is already represented in the
model through its tight association with peripheral
vascular disease (data not shown). An apparent
surprising finding is the lack of association betweenlar lesions
lar lesions p
Yes
35
60.8G6.5 NS
31 (89%) NS
6 (17%) NS
2 (6%) NS
11 (31%) NS
22 (63%) !0.001
4 (11%) NS
22 (63%) 0.033
34G19 0.052
25 (71%) NS
25 (71%) NS
9 (26%) NS
14 (40%) NS
, non-significant (pO0.1).
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Table 2. Relationship between clinical and laboratory variables and occult vascular lesions
Variables Occult vascular lesions p
No Yes
n 234 35
Body mass index (kg/m2) 28.8G4.4 27.5G3.9 NS
Abdominal circumference (cm) 103.4G11.0 100.4G10.4 NS
Mean systolic BP (mmHg) 127G19 133G21 0.059
Mean diastolic BP (mmHg) 79G11 77G12 NS
Pulse pressure (mmHg) 48G15 56G16 0.005
Total cholesterol (mg/dl) 191G41 186G36 NS
HDL cholesterol (mg/dl) 45.2G11.0 42.6G12.0 NS
LDL cholesterol (mg/dl) 119G35 118G30 NS
Triglycerides* (mg/dl) 114 (84–164) 119 (77–116) NS
Lp(a)* (mg/dl) 19.3 (9.6–50.4) 31.4 (11.3–75.7) 0.08
Apo A1 (mg/dl) 136G29 128G33 NS
Apo B (mg/dl) 96G24 97G22 NS
Creatinine (mg/dl) 1.10G0.22 1.19G0.35 NS
Glucose (mg/dl) 118G30 123G44 NS
HbA1cO7% 25 (11) 3 (9) NS
Microalbuminuria (O30 mg/g creat) 26 (11) 13 (37) !0.001
Hs-CRP* (mg/l) 2.4 (1.3–5.5) 5.0 (1.6–7.0) 0.095
Homocyst(e)in* (umol/l) 11.5 (9.3–14.1) 13.1 (10.9–17.3) 0.005
Data are meanGSD or number of cases (%) unless specified otherwise.
* Not normal variables were compared after logarithmic transformation and are expressed as median (interquartile range). NS, non-
significant (pO0.1).
S. Luja´n et al.60lipid parameters and OVL. However, it must be
emphasized that all patients had already established
vascular damage and a sizable proportion of patients
(likely those with higher initial values) were receiving
treatment with cholesterol lowering agents.
Our data demonstrate an association of higher
pulse pressure and OVL. Increased pulse pressure has
been identified as a predictor of long-term cardiovas-
cular risk, and has even been suggested for inclusion
in the Framingham risk score.9–12 A high pulse
pressure likely reflects increased stiffness of the
arterial bed. However, its relationship with occult
severe vascular lesions has not specifically been
addressed. Several authors have reported that a low
diastolic blood pressure (another indicator of the
stiffness of the arteries) was related to both OVL and
advanced atherosclerosis3,13 which is consistent with
our data. In spite of its interest, when evaluated byTable 3. Logistic regression models for occult vascular lesions
Unadjusted
Variable OR 95% CI p
Model 1
Microalbuminuria 4.2 1.7–10.5
Intermittent claudication 5.8 2.6–12.8 !
Model 2
Microalbuminuria 4.7 1.9–11.3
ABI%0.9 5.3 2.4–11.7 !
Model 3
Microalbuminuria 6.1 2.4–15.5 !
ABI per K0.1 units 1.32 1.14–1.53 !
Eur J Vasc Endovasc Surg Vol 30, July 2005multivariate logistic regression, pulse pressure was no
longer an independent predictor of OVL.
Microalbuminuria has been found to be a powerful
predictor of cardiovascular events both in diabetic and
non-diabetic patients.14,15 It is not surprising that in
our series microalbuminuria was a powerful predictor
of OVL. Several authors have described a similar
association between early markers of vascular damage
and microalbuminuria, particularly in diabetes.16–22 In
this regard, it is interesting to note that in our series,
neither diabetes by itself nor its short term control
(glycated hemoglobin) were predictors of OVL in spite
of the fact that microalbuminuria was particularly
prominent among diabetics (data not shown). It seems
thus, that the long-term consequences of diabetes,
such as microalbuminuria rather than diabetes itself
are most useful in predicting OVL.
An interesting finding of our study is the increasedAdjusted for age and sex
OR 95% CI p
.002 4.0 1.6–10.0 .003
.001 5.7 2.6–12.7 !.001
.001 4.6 1.8–113 .001
.001 5.1 2.3–11.4 !.001
.001 5.7 2.23–14.8 !.001
.001 1.13 1.14–1.52 !.001
Occult Vascular Lesions 61level of homocysteine in patients with OVL. However,
homocysteine was not an independent predictor of
OVL in multivariate analysis. A number of studies
have reported an independent association of hyperho-
mocysteinemia and cardiovascular disease.23 In con-
trast, most clinical studies have failed to show any
clinical benefit of homocysteine lowering therapies.24,25
Indeed, some authors have suggested that hyperhomo-
cysteinemia may be a marker of vascular damage,
rather than a causal risk factor, which is in agreement
with our results.
Finally, our study highlights the relevance of
peripheral vascular disease as a marker of severe
generalized atherosclerosis. First, when the initial
clinical presentation of atherosclerosis is peripheral
vascular disease (as opposed to coronary or cerebro-
vascular) the risk of occult severe vascular lesions is
higher. Second, peripheral vascular disease remains as
a powerful predictor when there are clinical manifes-
tations of other vascular beds. Therefore, peripheral
vascular disease must not be ignored or dismissed in
the presence of lesions of more ‘noble’ territories. And
third, peripheral vascular disease is an independent
powerful predictor in multivariate analysis. Both
clinically evident and subclinical disease had a similar
predictive power. In our series, asymptomatic periph-
eral vascular disease was present in less than 10% of
cases. However, other studies have reported a higher
frequency of clinically unapparent vascular disease,
further suggesting the need of ‘objective’ evaluation
such as the one provided by the ankle-brachial index.
Its inclusion in the clinical evaluation of coronary or
cerebrovascular disease may help identify patients
with a particularly high risk.
Our study has several important limitations. First of
all, although prospectively designed, its cross-sec-
tional nature is helpful in identifying clinical markers
rather than risk factors. Data regarding blood pressure
and lipid values should be interpreted with caution,
since a significant proportion of patients were receiv-
ing treatment with lipid and blood pressure lowering
drugs. However, this is the way we usually see
patients in the clinical setting, and, therefore, our
data may be of practical value. We have found that two
simple markers are particularly helpful in identifying
patients with unsuspected severe vascular lesions.
Most often microalbuminuria has been used as a
marker of increased cardiovascular risk before the
clinical manifestations of atherosclerosis. Here, we
report that microalbuminuria is still useful as a marker
of more advanced lesions after the appearance of
clinical vascular disease. Furthermore, the presence of
peripheral vascular disease (both clinical andsubclinical) is a powerful independent marker of
occult vascular lesions in different territories.
It is clear that not every patient with clinical
atherosclerosis have the same probability of having
an occult cardiovascular lesion. In this series, as well as
in the SMARTstudy, a small proportion of the patients
had an OVL. Thus, extensive screening of the vascular
tree may not be warranted in all atherosclerotic
patients. Our results suggest that two simple clinical
factors: presence of intermittent claudication and
microalbuminuria can help identify a subgroup of
patients with a particularly high risk of having OVL.Acknowledgements
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